Hemostasis and fibrinolysis in delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage: a systematic review

J Cereb Blood Flow Metab. 2015 May;35(5):724-33. doi: 10.1038/jcbfm.2015.13. Epub 2015 Feb 18.

Abstract

Delayed cerebral ischemia (DCI) after aneurysmal subarachnoid hemorrhage (aSAH) has been associated with microthrombosis, which can result from activated hemostasis, inhibited fibrinolysis, or both. We systematically searched the PUBMED and EMBASE databases to identify hemostatic or fibrinolytic parameters that can be used for the prediction or diagnosis of DCI, or that inform on the pathogenesis of DCI and may serve as treatment targets. We included 24 studies that fulfilled predefined criteria and described 39 biomarkers. Only one study fulfilled predefined criteria for high quality. Since no parameter on admission was associated with DCI and in none of the included studies blood was drawn at the time of clinical deterioration, none of the studied parameters can presently be used for the prediction or diagnosis of DCI. Regarding the pathogenesis of DCI, it was shown that compared with patients without DCI those with DCI had higher levels of von Willebrand factor and platelet activating factor in plasma 5 to 9 days after aSAH, membrane tissue factor in cerebrospinal fluid 5 to 9 days after aSAH, and D-dimer in plasma 11 to 14 days after aSAH. Confirmation in high-quality studies is needed to investigate whether these parameters can serve as targets for new intervention studies.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review
  • Systematic Review

MeSH terms

  • Animals
  • Biomarkers / metabolism
  • Brain Ischemia* / drug therapy
  • Brain Ischemia* / etiology
  • Brain Ischemia* / metabolism
  • Brain Ischemia* / physiopathology
  • Fibrinolysis*
  • Fibrinolytic Agents / therapeutic use*
  • Humans
  • Intracranial Aneurysm* / complications
  • Intracranial Aneurysm* / drug therapy
  • Intracranial Aneurysm* / metabolism
  • Intracranial Aneurysm* / physiopathology
  • Subarachnoid Hemorrhage* / complications
  • Subarachnoid Hemorrhage* / drug therapy
  • Subarachnoid Hemorrhage* / metabolism
  • Subarachnoid Hemorrhage* / physiopathology

Substances

  • Biomarkers
  • Fibrinolytic Agents